TOBACCO USE AND SPECIAL POPULATIONS: MENTAL HEALTH DISPARITIES

Jan Blalock, Ph.D.

Department of Behavioral Science

University of Texas MD Anderson Cancer Center

PUBLIC HEALTH SIGNIFICANCE

- 40.1% of individuals in U.S. with psychiatric disorder within past 12 months smoked compared to 21.3% of those without disorder
- People with psychiatric disorder within past 12 months represent 31.7% of all current smokers
- Between 2009-2011, 30.9% of all cigarettes smoked were smoked by people with psychiatric disorders
- People with psychiatric disorders smoke more heavily
 - 40% smoke more than 25-30 cigarettes per day vs. 15% in general population controls

Lawrence et al., BMC Public Health, 2009; 9:285; CDC, MMWR; 62; Feb 5, 2013; Lasser et al., JAMA, 2000; 284:2606


PUBLIC HEALTH SIGNIFICANCE

- In people with serious psychiatric disorders, leading causes of death are similar to general population and are smoking related--cardiovascular disease and cancer
 - But people with serious psychiatric disorders <u>die of these diseases on average 25 years</u> <u>earlier</u>
- Individuals hospitalized for a diagnoses of serious mental disorder from 1990 to 2005—standardized mortality ratios (compared to general population) for tobaccolinked disease:
 - Schizophrenia, SMR = 2.45 (95% CI 2.41-2.48)
 - Comprised 53% of total deaths
 - Bipolar Disorder, SMR = 1.57 (95% CI 1.53-1.62)
 - Comprised 48% of total deaths
 - Depressive Disorder, SMR = 1.95 (95% CI 1.93-1.98)
 - Comprised 50% of total deaths

Colton & Manderscheid, Prev Chronic Dis, 2006; 3:A42; Callaghan et al., J Psychiatric Review, 2014; 48:102-110

CHANGE IN SMOKING RATE IN PSYCHIATRIC VS. GENERAL POPULATION

 There is evidence that while smoking prevalence is declining in mentally well individuals, it is unchanged in those with comorbid psychiatric disorders



IMPLICATIONS FOR TOBACCO CONTROL

- Principle components of population health-based smoking cessation efforts—increasing price, education on health consequences, restricting use in public places
 - Have not been tailored to this population
 - May be less relevant or less effective for people dealing with mental illness
- Universal approach in tobacco control may have contributed to accrual of substantial inequalities in benefit within this population of smokers

Lawrence et al., BMC Public Health, 2009, 9:285

PSYCHIATRICALLY COMORBID SMOKERS AS A TOBACCO USE DISPARITY GROUP

- In a recent AJPH article, Williams et al. (2013) argued that smokers with comorbid psychiatric disorders should be designated as a tobacco use disparity group
- Evidence for Tobacco Use Disparity
 - Disproportionate Tobacco Consumption
 - Disproportionate Health Consequences
 - Disproportionate Economic Burden and Purchasing
 - Targeted Marking by Tobacco Industry
 - Reduced access to cessation services

PSYCHIATRICALLY COMORBID SMOKERS AS A TOBACCO USE DISPARITY GROUP

- Designation as a priority group could lead to greater scientific funding and evaluation of tailored treatments that may be more effective
- A national plan for addressing disparities in this group is needed, rather than relying on the work of individual researchers

RECOMMENDATIONS FOR ADDRESSING TOBACCO-RELATED HEALTH DISPARITIES

- Integrate smoking cessation treatments into mental health and addiction treatment settings
 - In line with American Psychiatric Association 2006 practice guidelines
 - Encourages assessment and assistance in quitting with motivational, behavioral and pharmacological treatment

Callaghan et al., J Psychiatric Review, 2014; 48:102-110;; Williams, JAMA Psychiatry, 2013; 70: 1261-1262; Schroeder & Morris, Annu. Rev. Public Health, 2010; 31:297-314; Hall & Prochaska, Annu Rev Clin Psychol, 2009; 5:409-431.

INTEGRATED CARE

- Address institutional barriers (e.g., staff training, funding, organizational climate)
 - Promote policies for smoke-free treatment campuses
 - Train mental health workforce in provision of smoking cessation interventions
 - Specialized curricula have been developed and are available (Hudman et al., 2009; Prochaska et al., 2009; Morris et al., 2009; Guydish et al., *Drug Alcohol Dep*, 2012; 121:30-37)
 - Address common misbeliefs
 - "Psychiatric patients do not want to quit." (20% in preparation phase)
 - "Psychiatric conditions may be aggravated by quitting." (not supported by recent studies)
 - Improve treatment centers' strategies for seeking Medicaid and Medicare reimbursement of tobacco treatment services

Callaghan et al., J Psychiatric Review, 2014; 48:102-110;; Williams, JAMA Psychiatry, 2013; 70: 1261-1262; Schroeder & Morris, Annu. Rev. Public Health, 2010; 31:297-314; Hall & Prochaska, Annu Rev Clin Psychol, 2009; Kalman et al., Clin Psych Rev, 2010; 30:12-24.

INTEGRATED CARE

- Use standard smoking cessation interventions, which are effective
- Review of 8 randomized clinical trials of pharmacological and/or psychological interventions in patients with schizophrenia, schizoaffective, bipolar or delusional disorders
 - Those with serious mental illness able to quit or reduce smoking with these standard treatments
 - Point prevalence abstinence ranged from 3.4% to 22.2% in intervention groups
 - Addition of bupropion resulted in RR = 2.76 (95% CI 1.48-5.16)—comparable to outcome in general population (RR = 1.69 (95% CI 1.53-1.85)
- Varenicline in schizophrenic smokers—12 week double blind placebo controlled trial
 - 7 day point prevalence in varenicline 19.0% vs. placebo (4.7%) at 12 weeks EOT
 - No differences in adverse events or changes in psychiatric symptoms
- Identify new interventions to address mechanisms specific to population

Hall & Prochaska, Annu Rev Clin Psychol, 2009; 5:409-431; Williams, JAMA Psychiatry, 2013; 70; Hitsman et al., The Canadian J of Psychiatry, 2009; 54:368-378; Banham & Gilbody, Addiction, 2010; 105:1176-1189; Williams, J Clin Psychiatry, 2012; 73:654-660

PRIMARY CARE

- Only 41.1% of individuals with DSM-IV disorder received treatment from any source in 12-month period—data from National Comorbidity Survey Replication
- Suggests treatment provided through mental health services will fail to reach the majority of smokers with mental health disorders
- Clinical Practice Guidelines for treating tobacco dependence
 - Recommend all clinical and health care delivery system systematically assess and treat all tobacco users

Wang et al., Arch Gen Psych, 2005; 62: 629-640.

PRIMARY CARE

- Data from 495 general practices in England
 - 49.3% received advice
 - 6.7% received prescription from smoking cessation medication
- Epidemiological survey of individuals seeing primary care provider in U.S. in past year
 - Smokers with substance and mental disorders received smoking cessation counseling at high rate (72.9%) and equal to those without disorders
 - Counseling significantly associated with quitting (31.3% vs. 6.0% no counseling)
- More research is needed

QUITLINES

- Initial studies suggest tailored quitline services may be effective for smokers with mental illness
- Assessment and treatment considerations
 - Add questions to standard intake to assess mental health diagnoses
 - Assess psychiatric stability and access to psychiatric care; provide referrals
 - Assess how mental health symptoms affected by quitting in past
 - Pharmacotherapy
 - Individualized to patient needs
 - Interaction with psychiatric medications
 - Counseling should use problem-solving focus
 - May require extended call length and frequency

Morris et al., J Amer Psychiatric Nurses Assoc, 2009;15:32-40

QUITLINES

- Ask-Advise-Connect Approach
 - Has been found effective in increasing enrollment of smokers from primary care and publically funded community health clinics
 - Train nurses to assess smoking status and provide brief advise to quit
 - Offer cessation advise via quitline
 - Directly connect patients willing to accept assistance with quitline via automatic links in the electronic health record
 - Proactive contact of patients by quitline personnel with 48 hours
 - Broad adoption by health care systems could increase reach to smokers with mental health disorders
 - More research needed on quitline approaches tailored for this population

Vidrine et al., JAMA Intern Med, 2013; 173:458-464; Vidrine et al., Am J Prev Med, 2013; 45:737-741